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E2The E4 (also called E1^E4) and E2 proteins of human papillomavirus type 16 are thought to be expressed
within the same cells of a lesion, and their open reading frames overlap, suggesting that they may have a
functional relationship. We have examined the effect of co-expression of these two proteins and found that
each enhances the level of the other. We also identiﬁed the N-terminus of E2 as the ﬁrst example of a viral
protein that directly binds the HPV16 E1^E4 protein. This appears to result in the E2 becoming less soluble
and promotes its relocation from the nucleus to the cytoplasm. In addition, the turnover of the E2 protein is
decreased in the presence of E1^E4. All this raises the possibility that E1^E4 acts to inﬂuence E2 activity by
varying the amount of available E2 in the cell.
Crown Copyright © 2009 Published by Elsevier Inc. All rights reserved.Introduction
Papillomaviruses (PV) are small DNA viruses that infect the
epithelial tissue of a variety of species (Howley and Lowy, 2006).
Human PV (HPV), are classed as being either low-risk, e.g. HPV type
11, or high-risk, e.g. HPV type 16. Low-risk viruses are associated with
benign lesions, whilst the lesions caused by high-risk types may
become malignant. HPV16 for example, can cause cervical cancer
(Walboomers et al., 1999). PV initially infect basal epithelial cells and
complete the virus life-cycle as these cells divide, differentiate and
move towards the epithelial surface (Doorbar, 2006). In the lower
layers the early proteins facilitate replication and maintenance of the
viral genomes, whilst in the upper layers there is a change in
expression pattern of the viral proteins associated with massive
ampliﬁcation of the number of viral genomes, followed by packaging
and eventual release of virions from the epithelial surface.
One of the ﬁrst viral proteins thought to be expressed in the virus
life-cycle is the nuclear protein E2, and its transcripts remain present
until viral DNA ampliﬁcation has occurred (Klumpp and Laimins,
1999). The E2 protein has a number of functions during the virus life-mcinto@nimr.mrc.ac.uk
na.sorathia@gmail.com
nimr.mrc.ac.uk (Q. Wang),
k (Y. Soneji),
09 Published by Elsevier Inc. All ricycle, including roles in viral DNA replication (Yang et al., 1991),
regulation of viral transcription (Spalholz et al., 1985), and segrega-
tion (Ilves et al., 1999) and packaging of viral genomes (Zhao et al.,
2000). The most well-characterized function of the HPVE2 protein is
its role in recruiting E1 protein (and other replication factors) to the
viral DNA to facilitate replication of the viral genomes. The E2 protein
is able to do this because it binds to both the viral origin of replication
and to E1, the viral DNA helicase protein. Another viral protein to
which HPV16 E2 has been found to bind is L2, the minor capsid
protein (Okoye et al., 2005). At least in BPV, this appears to result in
relocation of E2 to PML oncogenic domains (Day et al., 1998). Whilst
this interaction appears to have no effect on viral DNA replication, it
can affect the ability of E2 to transactivate (Okoye et al., 2005). The
exact effect of E2 on transcription during the virus life-cycle is unclear
but depending on the situation, E2 is able to both activate and repress
transcription from the viral early promoter. The ability of HPV16 E2 to
activate transcription appears to involve the cellular protein, Brd4
(McPhillips et al., 2006; Schweiger et al., 2006). An additional role for
E2 binding to Brd4, at least in BPV, has been proposed to be in
tethering viral genomes to the host chromosome (You et al., 2004).
Such attachment is essential if the viral genomes are to be maintained
in cycling cells, and another E2 binding protein, ChlR1, is thought to be
important for this to occur in a number of PV types, including HPV16
(Parish et al., 2006). Binding of E2 to one of the viral oncogenes, E7,
seems to recruit E7 ontomitotic chromosomes (Gammoh et al., 2006),
whilst binding to the other viral oncogene, E6, affects both E6-induced
degradation activity and the replication and transcriptional activitiesghts reserved.
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may also involve the cellular TopBP1 protein (Donaldson et al., 2007),
although the consequence of this in the virus life-cycle is not yet clear.
Despite its name, the HPV16 E1^E4 protein becomes abundant
relatively late during infection. Its appearance coincides with the
onset of viral DNA ampliﬁcation in the upper layers (Doorbar et al.,
1997), a correlation made particularly intriguing by the fact that it is a
cytoplasmic protein, whereas HPV DNA replication occurs in the
nucleus. However, a role for E1^E4 in viral DNA replication is sup-
ported by the observation that somemutant PV genomes that lack the
ability to express full-length E1^E4 have been shown to have altered
levels of viral DNA replication (Nakahara et al., 2005; Peh et al., 2004;
Wilson et al., 2005, 2007). The mechanism of this phenomenon is not
clear but a number of cellular binding partners and activities have
been described for the HPV16 E1^E4 protein. These include binding to
keratins leading to collapse of the cytokeratin network (Doorbar et al.,
1991; Wang et al., 2004); to cdk/cyclin complexes leading to arrest of
the cell cycle in G2 (Davy et al., 2006, 2005, 2002); to mitochondria
and the associated induction of apoptosis (Raj et al., 2004), and to a
DEAD-box RNA helicase (Doorbar et al., 2000). 16E1^E4 has been
observed to interact with a number of kinases including ERK (Wang et
al., 2009a), Cdk1 (Davy et al., 2005), Cdk2 (Davy et al., 2006) and SRPK
(Bell et al., 2007). Although the ability of 16E1^E4 to bind to itself is
also well characterized (McIntosh et al., 2008; Roberts et al., 1997;
Wang et al., 2004), unlike E2, as yet no other HPV proteins have been
identiﬁed to bind to 16E1^E4.
The E4 ORF lies within, but out of frame, with that of the E2 ORF, and
as these proteins can be expressed in the same cells in a lesion, we
decided to investigate the interplay between these two proteins. Co-
expression of E2 and E1^E4 in cells showed that the levels of both
proteins were increased by the presence of the other. The ability of
E1^E4 to stabilize E2 was particularly observed in the presence of
cycloheximide suggesting that the turn-over of E2 is being reduced and
is accompanied by a decrease in the solubility of the E2 protein.
Interestingly, E1^E4was found tobind to E2, theﬁrst timea viral protein
binding partner has been identiﬁed for the E1^E4 protein and this can
lead to a partial relocation of E2 from the nucleus to the cytoplasm.
Results
The HPV16 E2 protein enhances E1^E4 protein levels
The E2 and E1^E4 proteins are expressed from overlapping reading
frames during a natural infection suggesting that they may have
functions that are linked, so the effect of co-expression of these two
proteins was analyzed. Plasmids that express HPV16 E2 and E1^E4
were co-transfected into COS-7 cells, and the levels of E2 and E1^E4
protein at 24, 48 and 72 h post-transfection were analyzed in
triplicate byWestern blot (Fig. 1A). At 24 h the levels of E1^E4 protein
are not signiﬁcantly different in the absence and presence of E2, but by
48 h, and even more markedly at 72 h, the levels of E1^E4 are
signiﬁcantly elevated by the presence of E2. Co-transfection of a
plasmid that expresses β-galactosidase (β-gal) shows equivalent
levels of β-gal protein in the absence and presence of E2. This
indicates that the change in E1^E4 protein level is not due changes in
transfection efﬁciency or gross changes in cellular transcription. That
the effect of E2 on E1^E4 is more pronounced at later time-points is
perhaps not surprising. E1^E4 is a highly abundant protein in lesions
and it may be that its levels are not sufﬁciently high to be fully
functional until a couple of days after transient transfection.
The HPV16 E1^E4 protein stabilizes the E2 protein
From Fig. 1A, we thought that there might also be subtle
differences in the levels of E2 protein observed in the absence and
presence of E1^E4. To investigate this more thoroughly we utilizedcycloheximide (CHX), a drug that inhibits protein synthesis. The cells
were again co-transfected but some were treated with cycloheximide
for 8 h prior to harvest at 48 h post-transfection. The resulting protein
levels were analyzed by Western blot (Fig. 1B, left hand panel). The
levels of E2 protein can be clearly seen to decrease after treatment
with cycloheximide for 8 h, suggesting that this protein is turned over
relatively quickly in these cells. However, when E1^E4 is co-
transfected, the levels of E2 are not lowered by the cycloheximide,
suggesting that E1^E4 prevents the degradation of E2.
A key cellular binding partner of the 16E1^E4 protein is the
cytokeratin network. To determine whether association of E1^E4 with
the cytokeratin network was required for E2 stabilization, the
experiments were repeated using a mutant E1^E4 that lacked the
ﬁrst 17 amino acids of E1^E4. In the past, a mutant that lacks just the
keratin-binding motif would have been utilized but this mutant is not
found in natural infections. As we now have evidence that in
differentiating epithelium, E1^E4 expressed from the viral genome
can then be truncated to amino acid 17 (J. Khan and P. McIntosh,
unpublished data), we decided to use a mutant lacking the ﬁrst 17
amino acids to analyze any keratin requirement (Fig. 1B, right hand
panel). We found that as with wild-type E1^E4, the N-terminal
deletion mutant was also able to stabilize E2 suggesting that
association with keratin was not required for this process.
The E2 and E1^E4 proteins interact in cells
There aremanyways in which the proteinsmight be affecting each
other's levels, one of which is through binding, either directly or
indirectly to each other. To determine if the E2 and E1^E4 proteins can
associate in cells we used immunoﬂuorescence and immunoprecip-
itation. Normally the E2 protein is found predominantly in the
nucleus, whilst E1^E4 is a cytoplasmic protein. To seewhere in the cell
the E1^E4 protein associated with the E2 protein, immunoﬂuores-
cence was used. SiHa cells infected with recombinant adenoviruses
that express E1^E4 and E2 were ﬁxed at 24, 48 and 72 h post-
infection, immunostained and analyzed by ﬂuorescent microscopy
(Fig. 2A). Even at early time-points E2 can be seen to partially co-
localize with E1^E4 in the cytoplasm of some cells and this
phenomenon becomes increasingly apparent at later time-points.
Not all cells displayed this phenotype, and in many E1^E4 expressing
cells, the E2 staining resembled that expected of cells not expressing
E1^E4. To conﬁrm that the co-localization of the two proteins was not
due to the use of recombinant adenoviruses, COS-7 cells transfected
with plasmids that express the E1^E4 and E2 proteins were also
analyzed by immunoﬂuorescent microscopy, Fig. 2B, and again E2
could be found to co-localize with E1^E4. This suggests that the E2
protein can be relocalized from the nucleus to the cytoplasm by the
presence of E1^E4, potentially as a result of binding. We attempted to
address whether this same phenomenon could be observed in
differentiating epithelium containing HPV genomes. However despite
being able to easily detect E1^E4 protein, we were unable to detect
the E2 protein with the currently available antibodies and thus were
unable to address this question.
To support the hypothesis that the observed co-localization was
due to binding of E2 to E1^E4, co-immunoprecipitation experiments
were carried out. E1^E4 is a very insoluble protein, making it difﬁcult
to immunoprecipitate; typically only a small fraction of the protein is
soluble in the relativelymild detergents required to facilitate antibody
binding. Therefore to obtain a sufﬁcient quantity of E1^E4 that could
be immunoprecipitated from the mild detergent fraction, E1^E4 was
expressed from recombinant adenoviruses. These vectors were used
to express E1^E4, E2 and β-gal in cells. The NP-40 detergent-soluble
fraction was obtained and immunoprecipitated on anti-E1^E4
polyclonal antibody. The resultant precipitated protein was analyzed
by Western blot using anti-E1^E4 and anti-E2 antibodies (Fig. 3A).
The immunoprecipitated E1^E4 protein can be clearly detected at
Fig. 1. Levels of E1^E4 protein are enhanced by the presence of E2. (A) Triplicate experiments were performed in which plasmids that express the E2 and E1^E4 proteins were
transfected into cells together and separately. Cells were harvested at 24, 48 and 72 h post-transfection, and the levels of E2 and E1^E4 proteins analyzed by Western blotting. As a
control for transfection, the cells were co-transfected with a plasmid that expresses β-galactosidase (β-gal) and levels of β-gal protein were analyzed. The E1^E4 protein is detected
as two bands; a full-length protein and a lower N-terminally truncated protein. Total E1^E4 protein was quantiﬁed using ImageJ software and the mean levels represented as bar
charts±SEM. At 24 h, an unpaired, two-tailed t-test of the difference in E1^E4 levels between the E2 positive and negative cells shows no signiﬁcant difference (pN0.2), however at
48 and 72 h a signiﬁcant difference is detected (pb0.01). (B) Cells were transfected with plasmids that express β gal, wild-type or ΔN E1^E4, and/or E2, and some were treated with
cycloheximide for 8 h prior to harvesting to inhibit protein synthesis. All the cells were harvested at 48 h post-transfection, and the levels of E2, E1^E4, tubulin and β gal protein were
assessed byWestern blotting, and the levels of E2 quantiﬁed using ImageJ are represented in bar charts±SD. An unpaired, two-tailed t-test of the difference in E2 levels between the
E1^E4 positive and negative cells shows signiﬁcant differences (pb0.05) of 3- to 5-fold for wild-type and ΔN E1^E4.
268 C. Davy et al. / Virology 394 (2009) 266–275both 24 and 48 h in all extracts infected with recombinant
adenoviruses that express E1^E4. In contrast, E2 protein is only co-
immunoprecipitated from extracts that are infected with a mixture of
recombinant adenoviruses that express both E1^E4 and E2, and only
at 48 h post-infection. This suggests that at 48 h post-infection, the E2
protein is binding to the E1^E4 protein, in agreement with what is
observed by immunoﬂuorescence (Fig. 2).
This immunoprecipitation is only able to assess binding of E2 to
the NP-40-soluble fraction of total E1^E4 protein. In fact most of the
E1^E4 protein in the cell is not soluble in NP-40 and requires
extraction in SDS (Wang et al., 2004). Therefore to assess interaction
of various proteins with this relatively insoluble fraction of E1^E4, we
routinely use a solubility assay (Davy et al., 2006, 2005). In this case
we adapted our solubility assay to use a method used previously by
Donaldson et al. to monitor E2 solubility (Donaldson et al., 2007).
Cells were transfected with plasmids that express E1^E4 and/or E2,
and at 48 h post-transfection the cells were harvested andfractionated into triton- (similar properties to NP-40), NaCl- and
SDS-soluble fractions. These fractions were analyzed by Western blot
to determine the distribution of the proteins (Fig. 3B). The tubulin
control shows that the method has correctly fractionated this
relatively soluble protein, and that the loadings in the triton and
NaCl samples with and without E1^E4 are the same. The histone 2B
control shows that the method has correctly fractionated this
relatively insoluble protein and that the loadings in the SDS fraction
with andwithout E1^E4 are the same. As expected, the E1^E4 is found
predominantly in the SDS-soluble fraction. In the absence of E1^E4,
the E2 is found predominantly in the triton- and NaCl-soluble
fractions. However in the presence of E1^E4, a greater proportion of
the E2 is found in the SDS-soluble fraction, suggesting that E1^E4 has
desolubilized E2. Whilst not conclusive evidence of binding, these
data are indicative of an association between E2 and the relatively
insoluble E1^E4, and this supports our observation of binding in the
NP-40-soluble fraction (Fig. 3A). However, it is not clear whether the
Fig. 2. The E2 and E1^E4 proteins associate in cells. Cells were infected with recombinant adenoviruses (A), or infected with plasmids (B), that express E1^E4 and E2, and ﬁxed at 24,
48 or 72 h post-infection. Cells were immunostained for E1^E4 (green) and E2 (red). A DAPI nuclear stain was included (blue).
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cellular co-factors.
In vitro binding of E2 to E1^E4 can occur directly and involves the
N-terminus of E2 and the C-terminus of E1^E4
To test whether the interaction between the E2 and E1^E4
proteins is direct, in vitro pull-down assays were used (Fig. 4). The
ability of glutathione S transferase (GST)-tagged E2 (GST-E2) to
pull-down E1^E4 from cell extracts was assayed. GST and GST
fused to two HPV16 proteins, E1 and E5, were used as negative
controls, and because E1^E4 dimerizes, GST-E1^E4 was used as a
positive control (Fig. 4A). The ability of each of these GST fusion
proteins to bind E1^E4 was assessed for each of three cellular
fractions. The E1^E4 protein is predominantly insoluble in NP-40
(fraction N) and requires the harsher detergents Empigen BB
(fraction E), or urea (fraction U), to entirely solubilize it. Tofacilitate the pull-downs using the E and U fractions, these samples
were ﬁrst diluted 1:10 into an NP-40-based buffer. Even with this
dilution step it can be seen that the levels of E1^E4 in the E and U
fractions of the input are signiﬁcantly higher than that in the N
fraction (Fig. 4B). The E1^E4 was expressed from a recombinant
adenovirus in SiHa cells and in this cell line, as in infections caused
by HPV16, some of the E1^E4 is phosphorylated on T57 and this
causes a change in mobility of the E1^E4 on SDS gels resulting in
an upper band (Wang et al., 2009a). As expected, E1^E4 is pulled-
down from all three fractions using GST-E1^E4, and fails to be
pulled-down by GST alone (Fig. 4B). E1^E4 is also pulled down
speciﬁcally by the GST-E2 fusion protein and not by the fusion
proteins derived from other early HPV proteins that are expressed
at a similar time in vivo to E2 and E1^E4. The GST fusion of the E2
protein appears able to pull-down E1^E4, whilst the E1 and E5 GST
fusion proteins fail to pull down E1^E4. Whereas the GST-E1^E4
protein only pulls down the form of E1^E4 that is not
Fig. 3. The E2 and E1^E4 proteins bind in cells. (A) Cells were infectedwith recombinant
adenoviruses that express β-galactosidase (β-gal), E1^E4 or E2, or a mixture of E1^E4-
and E2-expressing adenoviruses. NP-40 detergent-soluble cell extracts were obtained
at 24 h and 48 h post-infection. Proteins were immunoprecipitated using anti-E1^E4
polyclonal antibody and analyzed by Western blotting using anti-16E1^E4 monoclonal
antibody, TVG402 (left hand blot) and anti-E2 monoclonal antibody, TVG261 (right-
hand blot). (B) Cells were transfected with plasmids that express E1^E4 and/or E2. At
48 h post-transfection the cells were fractionated into triton-, NaCl and SDS- soluble
fractions. The fractions were analyzed by Western blotting using anti-E1^E4 and anti-
E2 antibodies. Anti-tubulin and anti-histone 2B blots were included as controls for
fractionation.
Fig. 4. The E2 and E1^E4 proteins can interact directly. (A) GST and GST fusions of E1,
E2, E1^E4 and E5 were prepared from E. coli and puriﬁed on glutathione beads before
being separated by SDS-PAGE and stained with Coomassie. Arrowheads indicate bands
of the expected size for each protein. (B) Extracts from cells infected with recombinant
adenoviruses that express E1^E4 were fractionated into NP-40-, EmpigenBB- and urea-
soluble fractions. The EmpigenBB and urea fractions were diluted ten-fold into NP-40
buffer and then used with the neat NP-40 fraction in pull-downs with the GST-fusion
proteins. The pulled-down proteins were analyzed by Western blotting with anti-
E1^E4 antibodies. (C) The GST and GST fusions of E2 and E1^E4 were used in pull-
downs with histidine-tagged E1^E4 puriﬁed from E. coli. Pulled down proteins were
analyzed by Western blotting with anti-E1^E4 antibodies. (D) Extracts from cells
infected with recombinant adenoviruses that express E2 were used in pull-downs with
GST fusion proteins. The pulled-down proteins were analyzed byWestern blotting with
anti-E2 antibody.
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phosphorylated and –unphosphorylated forms of E1^E4.
These assays whilst supporting the observation that E2 and E1^E4
bind, still do not rule out the requirement of a cellular co-factor that
may be bound to the E1^E4 extracted from the SiHa cells. To rule out
this possibility, the pull-downs were repeated using histidine-tagged
E1^E4 (His-E1^E4), which had been prepared in Escherichia coli (Fig.
4C). As expected, His-E1^E4 bound to GST-E1^E4, and it also bound to
GST-E2. In this case, as the His-tagged protein was prepared in
bacteria, there is no phosphorylated E1^E4, but a truncated form, that
has been found to lack the N-terminus (McIntosh et al., 2008), is
present, suggesting that the N-terminus of the E1^E4 protein is not
required for binding to E2. To further conﬁrm the interaction, E2
expressed from recombinant adenoviruses in MCF7 cells was pulled
down on GST-E1^E4 but not GST (Fig. 4D). The data in Fig. 4 conﬁrm
that the interaction between E2 and E1^E4 is direct and suggest that
the interaction does not require the N-terminus of E1^E4. To
determine which regions of E1^E4 and E2 are interacting, GST pull-
downs were carried out using mutant E1^E4 and E2 proteins.
The HPV16 E2 protein is 365 amino acids long and composed of
two domains, the C-terminal DNA-binding and dimerization domain,
separated by a hinge region from the N-terminus that may also
dimerize (Antson et al., 2000) and which binds to a number of viral
and cellular proteins including, HPV E1 and Brd4. The HPV16 E1^E4
protein has a structure in which C-terminal beta-sheet folds back to
interact with the N-terminal helical region (McIntosh et al., 2008).
A panel of mutant GST-tagged E2 proteins was assessed for their
ability to bind to wild-type, His-tagged E1^E4 in pull-down assays(Fig. 5A). Full-length E2 pulls down E1^E4 whilst GST alone does not.
Both clones that contain the N-terminus of E2 (1–138 and 1–216) are
able to pull-down E1^E4, whilst the clones that lack the N-terminus
(194–365 and 237–365) are not. This suggests that E1^E4 binds to the
N-terminus of E2, somewhere within the ﬁrst 138 amino acids.
To try to identifywhere on E1^E4 theN-terminus of E2 is binding to,
a panel of 16E1^E4 proteins containing approximately ﬁve amino acid
deletionswas utilized (Fig. 5B). The ability of eachmutant to bindwild-
type E2 was assessed by pulling down His tagged versions of each
E1^E4 mutant on GST-E2 (Fig. 5C). It can be seen that whilst there is
abundant mutant 13 (Δ84–88) and 14 (Δ86–92) in the pull-downs,
very little E1^E4 protein is pulled down, suggesting that the C-terminus
region of 16E1^E4 is involved in binding to E2. Whilst the reduction in
binding to the C-terminalmutantswas consistently observed, the small
reductions in binding seen in other regions of the protein were not
always seen and may reﬂect difﬁculties in protein folding. To conﬁrm
that the lack of bindingofGST-E2 tomutantΔ84–88-E1^E4wasnot due
to instability and degradation of the Δ84–88-E1^E4 (mutant 13)
protein, the pull-downwas repeated and the fractions of E1^E4 binding
and not binding to GST-E2 were assayed for the two E1^E4 proteins
(Fig. 5D). As can be seen, the Δ84–88-E1^E4 protein is not just being
degraded, as it is present in the not bound (NB) fraction.
Together these data suggest that the N-terminus of E2 binds to the
C-terminus of E1^E4. The N-terminus of E2 is known to be involved in
a number of activities of the E2 protein including replication and
modulation of transcription and we have tested the effect of E1^E4 on
these activities (data not shown). However, difﬁculties associated
with assessing individual activities of a small protein like E1^E4 mean
that although we have observed that E1^E4 can affect replication of
HPV ori-containing plasmids, we have insufﬁcient evidence to claim
any speciﬁc E2 binding-mediated effects of E1^E4 on HPV replication.
Fig. 5. The association of E2 with E1^E4 occurs through the N-terminus of E2 and
involves the C-terminus of E4. (A) Pull-down using wild-type and mutant GST-tagged
E2 proteins and wild-type His-tagged E1^E4. Upper panel shows Coomasie-stained
membrane of pulled-down GST proteins. Numbers in parentheses indicate the amino
acids present in the mutants. Lower panel shows Western blot of pulled-down E1^E4
protein. (B) Amino acid sequence of the wild-type HPV16 E1^E4 protein. Black bars
indicate the amino acids deleted in each of fourteenmutants. (C) Pull-down using wild-
type and mutant His-tagged E1^E4 proteins and wild-type GST-E2. Upper panel shows
anti-His-tag Western blot of E1^E4 proteins used in pull-downs. Lower panel shows
anti-His-tag Western blot of E1^E4 proteins pulled-down by GST-E2. (D) Pull-down
using GST-tagged E2, and wild-type- and Δ84–88- His-tagged E1^E4. Levels of E1^E4
proteins bound (B) and not bound (NB) to GST-E2 were assayed by Western blot.
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transcription using standard luciferase-based assays. In some experi-
ments, no effect is apparent, whilst in others an effect is apparent but
this is cancelled out when the experiments are controlled for protein
amount suggesting that they are mediated not by direct E1^E4 effects
on E2, but more likely by, for example, E1^E4 effects on the cell cycle
or cell viability.
The C-terminus of E1^E4 is not absolutely required for association in
cells or elevation of E2 and E1^E4 levels
To begin to investigate the mechanisms by which E2 and E1^E4
can affect each other's levels, we set out to determine whetherbinding is required. To answer this question we expressed E2 and the
Δ84–88-E1^E4 that failed to bind E2 in vitro, and assayed for the
ability of E2 to affect the levels of E1^E4 (Fig. 6A), and for the ability of
E1^E4 to stabilize E2 (Fig. 6B). As can be seen in the absence of E2, the
levels of Δ84–88-E1^E4 are very low (Fig. 6A), as has been previously
reported for other C-terminal E1^E4 mutants (McIntosh et al., 2008;
Wang et al., 2004). However, in the presence of E2 the levels of E1^E4
are substantially increased (Fig. 6A), and the Δ84–88-E1^E4 protein is
able to rescue levels of the E2 protein in the presence of cyclo-
heximide (Fig. 6B).
Having found that using Δ84–88-E1^E4 neither abrogated the
ability of E1^E4 to stabilize E2, nor inhibited the ability of E2 to
increase the levels of E1^E4, we wondered if Δ84–88-E1^E4 does
indeed bind to E2 in cells but that the interaction is not sufﬁciently
robust to withstand the conditions used in GST-pull-downs. As
immunoprecipitation essentially uses the same washing steps as GST-
pull-downs, one might expect to be unable to co-immunoprecipitate
the relatively low levels of soluble Δ84–88-E1^E4 and E2. Therefore
we instead examined the cells using immunoﬂuorescent microscopy
(Fig. 6C) and found that the two proteins can have the same
localization. Unlike wild-type E1^E4, Δ84–88-E1^E4 is predominantly
nuclear, giving it ready access to nuclear E2. It is difﬁcult to say
whether the nuclear Δ84–88-E1^E4 is truly associating with the E2 as
both proteins are distributed widely throughout the nucleus and the
apparent co-localization may be non-speciﬁc. However, it can be seen
that some of the Δ84–88-E1^E4 remains in the cytoplasm, in the
perinuclear region, and E2 is observed to speciﬁcally occur in this
location and not in the rest of the cytoplasm, suggesting that E2 has
been relocated to this region by theΔ84–88-E1^E4. To further test this
potential association we assayed the ability of Δ84–88-E1^E4 to
desolubilize E2 (Fig. 6D). The solubility of Δ84–88-E1^E4 is different
from that of wild-type in that a large proportion of Δ84–88-E1^E4 can
be solubilized in 0.5% triton, although a signiﬁcant amount ofΔ84–88-
E1^E4 does require 5% SDS to solubilize it. As for wild-type E1^E4, the
Δ84–88-E1^E4 appears able to desolubilize E2. These data support the
immunoﬂuorescence data in suggesting that Δ84–88-E1^E4 can
associate with E2.
Together these results show that the abilities of the proteins to
affect each other's levels may indeed involve them associating. We
have tried to deﬁnitely show this by making tagged-E2 mutants that
do not bind to E1^E4 and expressing them in cells. However, we have
been unable to make and detect such a mutant, suggesting that the
region to which E1^E4 binds is important for producing a correctly
folded E2 protein that is stable in cells. Whilst the Δ84–88-E1^E4 was
thus not the ultimate non-binding mutant to assay, it has been useful
in suggesting that either E2 binds preferentially to insoluble E1^E4 or
that it is the insoluble E1^E4 that is more able to stabilize E2. Either
way, interestingly the E2 accumulates in the insoluble fraction
irrespective of the proportion of E1^E4 that is found in that fraction
(Figs. 3B and 6D).
Discussion
In this paperwe have identiﬁed E2 as the ﬁrst viral protein found to
bind to theHPV16 E1^E4 protein, and discovered that co-expression of
the two proteins results in a number of interesting phenomena,
including changes in protein solubility, stability and localization.
The fact that these two viral proteins interact is perhaps not
surprising given their overlapping ORFs and predicted co-expression
within HPV-induced lesions. However, why might E2 want to
regulate E1^E4 levels? Previous work on E1^E4 has suggested that
the role of E1^E4 may change according to its levels within the
cell (Davy et al., 2005), so it is possible that during a natural
infection, E2 acts to modulate E1^E4 function by affecting its levels.
Although the exact role of E1^E4 in the virus life-cycle is not yet
known, its potential function as an E2 accessory protein should not
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direct effect of E1^E4, for example on viral DNA ampliﬁcation, will
need to be dissected from any indirect effect on replication
mediated by E2.One way in which such indirect effects might be facilitated by
E1^E4 is by regulating the turnover of E2. In the context of our
experiments, this was only readily apparent in the presence of
cycloheximide, but under natural infection conditions, where endog-
enous levels of E2 are relatively low, this ability of E1^E4 may have
signiﬁcant effects on these levels. So why might E1^E4 want to
modulate E2 levels? There are several lines of evidence to suggest that
the activities of E2 within a cell are likely to be affected by the amount
of available E2 protein and oneway of controlling this is to prevent the
turnover of this protein. E2 has been shown to be ubiquitinated in its
N-terminal domain and degraded by the proteasome (Bellanger et al.,
2001; Penrose and McBride, 2000). This process appears to be
regulated in BPV by phosphorylation (Penrose and McBride, 2000)
and also by binding of HPV E2 to other proteins. Two recent papers
(Gagnon et al., 2009; Lee and Chiang, 2009) have shown the ability of
the Brd4 protein to regulate levels of HPV E2, whilst another (Wang et
al., 2009b) shows a similar effect mediated by the Tax1BP1 protein.
Lee and Chiang (2009) propose that Brd4may stabilize E2 by blocking
ubiquitination or proteosome binding, or by inhibiting phosphoryla-
tion, and it will be interesting to see whether Brd4, TaxBP1 and E1^E4
adopt the same strategy for E2 stabilization. Gagnon et al. (2009)
show that it is only a sub-population of the E2 molecules that are
stabilized by Brd4, and that at any one time the majority of the E2
molecules are not bound to Brd4. We seem to observe a similar
phenomenon in our assays in that only a proportion of the E2 is
interacting with E1^E4. This is apparent in that only a fraction of the
E2 seems relocated to the cytoplasm or desolubilized. It is possible
that the interaction of the two proteins is in some way regulated by
inﬂuences from the cell cycle. This may either be via direct effects of
such temporal pathways on the ability of the two proteins to bind, or
as a result of our previous observation that the cell cycle can affect the
levels of the E1^E4 protein (Davy et al., 2006). In any analysis of this
possibility it must be remembered that in addition to E1^E4 levels
being regulated by the cell cycle, E1^E4 protein can prevent cell cycle
progression (Davy et al., 2002). It seems plausible that different E2
binding partners may stabilize different E2 populations at different
times, and that this may act to regulate different E2 functions.
In addition to regulating levels of E2, the effect of E1^E4 on E2
solubility may also be of potential signiﬁcance, as redistribution of E2
to less soluble fractions probably reduces the amount of E2 available
for the functions it normally performs. This apparent contradiction in
the two activities of E1^E4; one to stabilize the protein thereby
potentially increasing levels of E2 activity, and two to desolubilize it,
thereby potentially decreasing E2 activity, can be rationalized by the
fact that these two effects might be important at different times
during the virus lifecycle. The expression, abundance and solubility of
E1^E4 is known to vary with the cell cycle (Davy et al., 2006) and
within the differentiating epithelium (Doorbar et al., 1997), and it
may be that in the context of an actual infection, the E1^E4 would
show a greater propensity at different times for either stabilization or
desolubilization of E2. The solubility of E2 has been observed toFig. 6. The C-terminus of E1^E4 may not be absolutely required for association with E2
and is not needed for the ability of the two proteins to affect each others' levels. (A)
Cells were transfected in triplicate with plasmids that express β-gal, E2 and/or Δ84–88
E1^E4. (B) Cells were transfected with combinations of plasmids that express β-gal, E2,
wild-type and/or Δ84–88 E1^E4, and some cells were treated with cycloheximide for
8 h prior to harvest to inhibit protein synthesis. In both (A) and (B), the cells were
harvested at 48 h post-transfection and were analyzed by Western blot for β–gal, E2
and wild-type or Δ84–88 E1^E4. (C) Cells transfected with plasmids that express Δ84–
88-E1^E4 and E2 were ﬁxed at 48 h post-transfection. Cells were immunostained for
Δ84–88-E1^E4 (green) and E2 (red). A DAPI nuclear stain was included (blue). Arrows
indicate the presence of Δ84–88-E1^E4 and E2 in the cytoplasm. (D) Cells were
transfected with plasmids that express Δ84–88-E1^E4 and/or E2. At 48 h post-
transfection the cells were fractionated into triton-, NaCl and SDS- soluble fractions. The
fractions were analyzed by Western blotting using anti-E1^E4 and anti-E2 antibodies.
Anti-tubulin and anti-histone 2B blots were included as controls for fractionation.
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2007). As for TopBP1, the functional outcome of the E1^E4-induced E2
solubility change is not yet apparent but it may be that both E1^E4 and
TopBP1 can modulate some aspect of E2 function by affecting its sub-
cellular distribution.However,with the increasingnumber of activities
being described for the E2 protein, and the likelihood of mutations
affecting other aspects of the protein's fold, the use of mutants to pin
down a particular part of the protein to a function seems problematic
and more sophisticated methods of inquiry may be needed. This is
similarly the case with E1^E4; a relatively small protein with multiple
activities. In fact it seems plausible that the observations made of the
Δ84–88-E1^E4 protein might be a result of abnormal structure of the
molecule rather than a direct deletion of the E2 binding motif. The C-
terminal region containing amino acids 84–88 is known to be involved
in multimerization of E1^E4 (Roberts et al., 1997) and the structure of
the wild-type E1^E4 protein has been recently shown to involve
folding back of this region onto the N-terminus (McIntosh et al., 2008).
Perhaps the apparent increased ability of Δ84–88-E1^E4 to desolubi-
lize E2 is a result of the inability of this mutant to multimerize. This
might be because the formation of E1^E4multimers stearically hinders
binding of E2, or it might be an indirect effect such as the increased
propensity formonomericΔ84–88-E1^E4 to enter the nucleus allowing
it more access to E2. It may be that in vitro, the reduction in stability of
the overall GST-E1^E4 fold associated with loss of the residues 84–88
causes structural changes that destabilize E2 binding. As such our
experiments have not necessarily demonstrated that binding has
minimal effect on E2 stability or protein levels, only that an E1^E4
mutant that does not bindwell to E2 in vitro, is still capable of stabilizing
E2 when expressed in cells. As we have been unable to identify any
stable E1^E4mutants that convincingly fail to associate with E2 in cells,
it may be that as with TopBP1 (Donaldson et al., 2007), the interaction
between E1^E4 and E2 is complex and again will require alternative
methods of analysis to deduce whether the changes in solubility,
stability and localizationobserved as a result of co-expressiondo require
a physical association of the two proteins. Whatever the mechanisms
turn out to be, it will be interesting to see if these changes correlatewith
effects on known functions of E2 within the virus life-cycle.
Materials and methods
Constructs used for in vitro pull-downs
Vectors expressing full-length E1, E2 and E1^E4 fused to
glutathione S-transferase (GST) have been previously described;
pGEX.16E1 (Hibma et al., 1995), pGEX.16E2 (Hibma et al., 1995) and
pGEX.16E1^E4 (Doorbar et al., 1992), respectively. The pGEX.16E5
vector was constructed by PCR ampliﬁcation of the E5 ORF from the
W12 genome (Stanley et al., 1989) using the primers tattacagtg-
gatcctggatttat and atgtaagaattcattatgtacata, and the resulting frag-
ment was cloned into pGEX using the BamHI and EcoRI sites. The
plasmids that express mutant E2 proteins were kind gifts from L.
Banks, ICGEB, Italy (E2 1–138 and 237–365), and P. Howley, Harvard
University, USA (E2 1–216 and 194–365). Histidine tagged 16E1^E4
was produced by sub-cloning mutants generated by S. Roberts,
University of Birmingham, UK, using the primers gggccctcggtttccatg-
gctgatcctgcagcagca (forward wild-type and mutants 2–14), tatataac-
tctcgagtgggtgtagtgttactattac (reverse wild-type and mutants 1–12),
cttgatccatggcagcaacgaagtatcctctc (forward mutant 1), gtgactctcgag-
tgggtgtagtgttccgtcc (reverse mutant 13), gtgactctcgagagttaatccgtc-
ctttgtgtg (reverse mutant 14) into the XhoI and NcoI sites of pET28b
(Novagen).
Protein expression and puriﬁcation for in vitro pull-downs
Expression in BL21 cells and puriﬁcation of the GST and GST fusion
proteins was essentially as previously described (Keen et al., 1994),however the extraction method was modiﬁed to improve extraction
of low solubility GST fusion proteins, such as GSTE1 and GSTE5. For
these proteins N-Lauroyl sarcosine (sarkosyl) detergent lysis was
combined with sonication (Frangioni and Neel, 1993). Proteins were
recovered from cleared lysates by immobilization on glutathione-
Sepharose beads at 4 °C for 1 h. The beads were then washed twice
with TEN-100, followed by two washes with NET-N (0.5% NP-40,
20 mM Tris-Cl pH 7.4, 0.1 mM EDTA, 300 mM NaCl), both containing
5 mM ATP and protease inhibitors.
Expression in BL21 cells and puriﬁcation of the His-tagged wild-
type and mutant E1^E4 proteins by nickel-afﬁnity puriﬁcation has
been previously described (Wang et al., 2004). The proteins were
refolded by dilution and dialysis into three changes of TEN-100 buffer
(20 mM Tris-Cl pH 7.4, 1 mM EDTA, 100 mM NaCl), containing 2 mM
DTT.
Proteins were separated on 4–12% Bis-Tris gradient gels (Invitro-
gen) by sodium dodecyl sulfate-polyacrylamide gel electrophoresis
(SDS-PAGE) before silver or Coomassie blue staining to assess purity.
Pull-downs
The protein loading of the glutathione beads differed for the
various fusion proteins, hence different volumes of beads were used
to ensure comparable amounts of each GST protein were used in the
pull down experiments. To maintain a constant bead volume in each
pull down, samples were supplemented with glutathione-Sepharose
bead slurry to a total volume of 120 μl of 33% slurry. Beads were
incubated with cell fractions (see below) or histidine tagged wild-
type or mutant E1^E4, at equivalent concentrations, in a total volume
of 500 μl of NET-N buffer for 1 h at 4 °C. The beads were harvested by
centrifugation and washed three times with 10 bed volumes of NET-
N; DTT. Bound proteinswere eluted from the beads on heating at 95 °C
for 5 min in 50 μl of SDS-sample buffer and were analyzed by western
blotting.
Cell culture, transfection and infection with recombinant adenoviruses
SiHa cells were infected with recombinant adenoviruses that
express 16E1^E4 (rAd.16E1^E4), 16E2 (rAdE2) and β-galactosidase
(rAd.β-gal) at a total combined multiplicity of infection of 200,
essentially as previously described (Davy et al., 2002). The MV11.ΔN.
E1^E4 was cloned by PCR ampliﬁcation using MV11.16E1^E4 as a
template and accggtaccgccaccatgagcacttggccaaccaccccgccgcga and
ggaattccggatccttatgggtgtagtgttactatt primers The resulting PCR pro-
duct was cloned into the KpnI and EcoRI sites of MV11. For trans-
fections, pCDNA6.β-gal, pMV11, pMV11.16E1^E4 and pMV11.16E2
(Davy et al., 2002) were prepared using the EndoFree Plasmid Maxi
Kit (QIAGEN) and transfected into COS-7 cells using Effectene
(QIAGEN).
Solubility fractionation
To obtain fractions for use in GST pull-downs, SiHa cells that
expressed 16E1^E4 from recombinant adenoviruses, were lysed in
NP-40 lysis buffer (PBS containing 0.5% NP-40 and protease
inhibitors), and the NP-40-soluble supernatant was obtained by
centrifugation (10,000g, 15 min, 4 °C). The pellet was resuspended in
lysis buffer containing 0.8% Empigen BB and again centrifuged to
obtain the Empigen-soluble supernatant. The pellet was solubilized
in 9 M urea in PBS to obtain the urea fraction. To obtain frac-
tions for Western blotting, Cos-7 cells transfected with pMV11,
pMV11.16E1^E4 and pMV11.16E2 were fractionated using a previ-
ously described method (Donaldson et al., 2007). In brief, cells were
fractionated using gentle detergent (0.5% Triton), then high salt (1 M
NaCl) and ﬁnally 5% SDS; 5 mM DTT, before being separated by
SDS-PAGE.
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2×106 recombinant adenovirus-infected cells were lysed in 200 μl
of 1% NP-40 in buffer A (10 mM EDTA, 0.5 μg/ml okadaic acid, 1 tablet
per 10 ml of mini protease inhibitor cocktail, (Roche), in PBS) on ice
for 30 min centrifuged at 14,000 rpm for 15 min. The supernatants
were mixed with 200 μl of buffer A containing 0.25% gelatin, and
incubated for 2 h at 4 °C with 10 μl rabbit anti-16E1^E4 polyclonal
antibody. Complexes were pulled down on Protein G Sepharose
(Amersham Pharmacia Biotech). Samples were separated on 15% SDS
polyacrylamide gels and analyzed by Western blotting. For Western
blotting, samples were separated by SDS-PAGE and transferred to an
Immobilon P membrane (Millipore). Detection was with anti-
16E1^E4 clone TVG402 (Doorbar et al., 1992), anti-E2 clone TVG261
(Millipore), anti-β-gal polyclonal 55976 (ICN Biomedicals), anti-
tubulin clone B512 (Sigma), anti-histone 2B clone 371 (Upstate
Biotechnology) or anti-GAPDH clone 374 (Chemicon), then anti-
rabbit (NA9340) or anti-mouse (NA931) HRP-conjugates (GE Health-
care), followed by detection using the ECL, or ECL plus kits (GE
Healthcare).
Immunomicroscopy
Cells were ﬁxed for 5 min in 5% formaldehyde in PBS, blocked in 2%
BSA in PBS for 30 min at 4 °C and permeabilized in 0.1% Triton X-100
in PBS for 10 min. Cells were incubated with primary antibodies
diluted in 0.1% FCS in PBS at room temperature for 1 h. Nuclei were
stainedwith 1 μgml−1 DAPI (4′-6-diamidino-2-phenylindole; Sigma).
HPV16 E1^E4 and E2 proteins were detected respectively using
TVG405 antibody (Doorbar et al., 1992) directly conjugated to Alexa-
Fluor 488 (Molecular Probes), and TVG261 antibody (Millipore),
followed by Alexa-Fluor 594-conjugated anti-mouse antibody (Mo-
lecular Probes). The cells were examined using a ﬂuorescent Labophot
II monochrome camera (Nikon), digital images were captured using a
SenSys monochrome camera, and ﬂuorescent signals were overlaid
using IP Lab imaging software (Roper Scientiﬁc).
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